| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 江苏康为世纪生物科技股份有限公司（简称“康为世纪”）是一家立足于生命科学和大健康领域，具有自主知识产权的国家高新技术企业。公司于2022年成功登陆上交所科创板（股票代码为688426）。 康为世纪秉承“让每一个生命健康有为”的使命，始终致力于分子检测核心原料酶的自主研发并实现进口替代，在分子检测领域积累了丰富的技术研发优势并获得过百项专利技术，参与了多项国家标准和行业标准的开发和制定，为多个生命科学细分领域提供超过700款创新型产品。核心产品包括多款分子检测核心原料酶、核酸保存、提取和纯化试剂及高通量测序试剂盒等，并全面布局三代测序、微生物绝对定量检测、核酸质谱等前沿方向和新兴产业，积极投身于消化道疾病和呼吸道传染病的筛查和诊断领域，打造出幽门螺杆菌感染与耐药一体化检测技术平台，实现了“核心原料酶+试剂盒+分析仪器+定制服务”的一体化创新解决方案。 | ||||||||||||||||||||||||
| Main Business | 分子检测底层核心技术的自主研发。 | ||||||||||||||||||||||||
| Legal Representative | 王春香 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 戚玉柏 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 大华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0523-86200880 | ||||||||||||||||||||||||
| Fax No | 0523-86200880 | ||||||||||||||||||||||||
| Website | www.cwbio.com | ||||||||||||||||||||||||
| cw688426@cwbio.cn;IRM@cwbio.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 25/10/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.977 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 12.011 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.369B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |